Please login to the form below

Not currently logged in
Email:
Password:

Iressa

This page shows the latest Iressa news and features for those working in and with pharma, biotech and healthcare.

Tagrisso tops rival drugs on survival in first-line lung cancer

Tagrisso tops rival drugs on survival in first-line lung cancer

The improvement in OS came over other drugs in the EGFR inhibitor class, namely AZ’s own Iressa (gefitinib) and Roche’s Tarceva (erlotinib), and according to AZ’s head of

Latest news

  • AstraZenca to appeal NICE rejection of Tagrisso AstraZenca to appeal NICE rejection of Tagrisso

    targeting drug Iressa, which is already recommended by NICE, with median patient survival at 34.1 months compared to 26.8 months. ... Vizimpro also increased the length of time before disease progression compared to gefitinib, with 14.7 months for

  • Pfizer gets EU nod for Tagrisso rival Vizimpro Pfizer gets EU nod for Tagrisso rival Vizimpro

    Undeterred, Pfizer ran a third trial called ARCHER 1050 that showed Vizimpro was able to extend progression-free survival (PFS) compared to AZ’s first-generation EGFR inhibitor Iressa (gefitinib), although ... Now, with approval on both sides of the

  • Tecentriq combo gains European NSCLC approval Tecentriq combo gains European NSCLC approval

    The regimen is approved only after the failure of appropriate targeted therapies though, including AstraZeneca’s Tagrisso and Iressa.

  • Pfizer closes on EU approval of lung cancer drug Vizimpro Pfizer closes on EU approval of lung cancer drug Vizimpro

    Pfizer persisted with a third study that showed Vizimpro was able to extend progression-free survival (PFS) compared to AZ’s first-generation EGFR inhibitor Iressa (gefitinib). ... Vizimpro will now be able to compete directly with Iressa, Roche’s

  • FDA approval gained, Pfizer sets sights on first-line NSCLC market FDA approval gained, Pfizer sets sights on first-line NSCLC market

    The second-generation EGFR tyrosine kinase inhibitor has been shown in trials to be more effective that first-generation drugs such as AstraZeneca’s Iressa (gefitinib) and Roche’s Tarceva (erlotinib) ... It showed that dacomitinib extended progression

More from news
Approximately 6 fully matching, plus 72 partially matching documents found.

Latest Intelligence

  • Is China ready for a pharmaceutical gold rush?

    2016 saw GlaxoSmithKline (GSK) slash the price of its hepatitis drug Viread by two-thirds, and AstraZeneca halved the price of cancer drug Iressa, leading to a 16% decline in sales.

  • Transforming times at AstraZeneca Transforming times at AstraZeneca

    It is a particularly pressing matter for AZ considering the company has several personalised medicines on market or in development, including Iressa (gefitinib) to treat lung cancer patients with a mutation

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    If approved, the drug would complement AZ's other NSCLC drug, Iressa, which is approved in NSCLC patients with the EGFR mutation. ... Another development is AZD9291 – a drug which addresses the T790M mutation, which is a key resistance mechanism to

  • Payer focus in the personalised world of oncology and orphan diseases Payer focus in the personalised world of oncology and orphan diseases

    more effective (eg Herceptin in HER2+ breast cancer, Iressa and Tarceva in EGFR mutation+ non-small cell lung cancer and Glivec in Philadelphia chromosome+ CML).

  • Market access opportunities in China Market access opportunities in China

    In part as a result of these efforts, both Tarceva and Iressa have been appraised in the Guideline for Diagnosis and Treatment of Primary Lung Cancer published by the Ministry of

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

Article: Like, Like, Like: Harnessing the power of social media insights
...
Its Know Your Numbers week
Do you know yours?...
What is changing in mental health and dementia care?
Paul Midgley, of Wilmington Healthcare, takes a look at the NHS Long Term Plan's bid to transform mental health and dementia services...

Infographics